<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-38795" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Alpha-Lipoic Acid</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Hiep</given-names>
          </name>
          <aff>Christus Health</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Pellegrini</surname>
            <given-names>Mark V.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hiep Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Pellegrini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-38795.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Alpha-lipoic acid (ALA) is a&#x000a0;supplement for managing chronic diseases characterized by oxidative stress, notably diabetic neuropathy, and demonstrates promise in slowing the onset of metabolic syndrome through&#x000a0;antioxidant properties. This supplement&#x000a0;exhibits multifaceted features,&#x000a0;functioning as an antioxidant&#x000a0;by mitigating oxidative stress-induced damage linked to chronic metabolic disorders. This activity elucidates the diverse indications, mechanism of action, contraindications, and crucial aspects of&#x000a0;ALA&#x000a0;supplementation, providing an understanding for healthcare team members&#x000a0;to manage chronic oxidative stress-related conditions.</p>
        <p>The in-depth exploration of ALA's mechanisms and therapeutic implications for oxidative stress-related chronic disorders, particularly diabetic neuropathy and metabolic syndrome, equips healthcare professionals with essential insights. Optimizing outcomes for chronic metabolic disorders associated with oxidative stress requires a multidisciplinary approach that considers the diverse benefits and limitations of ALA.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the clinical conditions associated with oxidative stress where alpha-lipoic acid supplementation is beneficial, such as diabetic neuropathy, metabolic syndrome, and other chronic diseases linked to increased oxidative damage.</p></list-item><list-item><p>Screen patients with chronic diseases, particularly diabetes mellitus, to assess their eligibility for alpha-lipoic acid supplementation, considering factors such as concurrent medications, allergies, and comorbidities.</p></list-item><list-item><p>Implement appropriate strategies for alpha-lipoic acid administration, including dosage regimens, administration protocols, and monitoring techniques to ensure patient compliance and safety.</p></list-item><list-item><p>Communicate the rationale, risks, benefits, and adverse effects of alpha-lipoic acid therapy with patients, ensuring informed consent and adherence to treatment plans.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38795&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38795">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-38795.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Alpha-lipoic acid (ALA) is a caprylic acid-derived antioxidant.&#x000a0;The compound is synthesized in the mitochondria and is a cofactor in the enzymatic nutrient breakdown.<xref ref-type="bibr" rid="article-38795.r1">[1]</xref>&#x000a0;ALA is also available in red meat, beets, carrots, potatoes, spinach, and broccoli. ALA consists of a dithiol functional group that eliminates&#x000a0;reactive oxygen species (ROS) by reducing&#x000a0;the oxidized forms of other antioxidants.<xref ref-type="bibr" rid="article-38795.r2">[2]</xref>&#x000a0;The organosulfur compound was discovered in 1937 when scientists found a type of bacteria that uses potato juice for reproduction.<xref ref-type="bibr" rid="article-38795.r3">[3]</xref>&#x000a0;</p>
        <p>ALA has recently gained a reputation as an antioxidant. In&#x000a0;the reduced form, dihydrolipoate reacts and neutralizes ROS, such as superoxide radicals, singlet oxygen, and hydroxyl radicals. Thus,&#x000a0;ALA is highly beneficial in several oxidative-stress-associated conditions such as ischemia-reperfusion or radiation injury.<xref ref-type="bibr" rid="article-38795.r4">[4]</xref>&#x000a0;</p>
        <p>Secondly, numerous studies have strongly supported the role of ALA in treating diabetic neuropathy.&#x000a0;ALA does so by enhancing nitric oxide-mediated endothelium-dependent vasodilation, improving microcirculation in patients with diabetic polyneuropathy.<xref ref-type="bibr" rid="article-38795.r5">[5]</xref>&#x000a0;Additionally, when taken with avocado or soybean unsaponifiable compounds, ALA is shown to significantly suppress prostaglandin E-2 production, a key cytokine in the pathogenesis of inflammation.<xref ref-type="bibr" rid="article-38795.r6">[6]</xref></p>
        <p>ALA possesses an excellent iron-chelation property.&#x000a0;The thiol groups in ALA are responsible for chelating irons. By increasing the glutathione levels inside the cells, ALA and dihydrolipoate excrete toxins, especially toxic metals, into the body. Lipoic acid&#x000a0;preferentially binds to &#x000a0;Zn, Pb, and Cu. On the other hand, dihydrolipoate forms complexes with&#x000a0;Fe, Zn, Hg, Pb, and&#x000a0;Cu.<xref ref-type="bibr" rid="article-38795.r7">[7]</xref></p>
        <p>So far, ALA has the most substantial evidence of&#x000a0;the therapeutic effect in diabetic neuropathy and oxidative stress conditions. There is still a need for more studies on the&#x000a0;benefits of other conditions&#x000a0;such as&#x000a0;HIV/AIDS, liver disease, and weight loss. According to the FDA, ALA is safe and effective, and promising uses can be explored in future studies.&#x000a0;</p>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>ALA has no approved indication as a dietary supplement available over the counter.</p>
      </sec>
      <sec id="article-38795.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>The dithiolane ring dictates ALA's chemical reactivity. Two forms of ALA are oxidized lipoic acid (LA) and reduced dihydrolipoic acid (DHLA). Both are capable of&#x000a0;scavenging&#x000a0;a variety of ROS. DHLA is a potent antioxidant that can neutralize free radicals. Furthermore, ALA simultaneously regenerates other antioxidant factors, such as vitamins C and E, increasing glutathione synthesis.<xref ref-type="bibr" rid="article-38795.r7">[7]</xref>&#x000a0;ALA&#x000a0;is generally involved in keto acid oxidative decarboxylation processes and&#x000a0;is a growth factor for some organisms.<xref ref-type="bibr" rid="article-38795.r8">[8]</xref></p>
        <p>In&#x000a0;the pathogenesis of inflammation, factor NF-kB modulates inflammatory cytokines, including&#x000a0;interleukins (ILs) such as IL-1&#x003b2; and IL-6. ALA inhibits I Kappa B kinase, suppressing the activation of inflammatory cytokines.<xref ref-type="bibr" rid="article-38795.r9">[9]</xref></p>
        <p><bold>Pharmacokinetics:&#x000a0;</bold>Absorption, volume of distribution, metabolism, and excretion are&#x000a0;not well-established for ALA.</p>
      </sec>
      <sec id="article-38795.s4" sec-type="Administration">
        <title>Administration</title>
        <p>ALA is available&#x000a0;as&#x000a0;an oral supplement and intravenous injection. Studies&#x000a0;postulate promising therapeutic properties in several conditions, including&#x000a0;type 1 and 2 diabetes mellitus (DM), neuropathy, and ischemic-perfusion injury.&#x000a0;</p>
        <p>Oral:&#x000a0;Data demonstrates that daily oral supplementation of 300 mg of ALA over 3 months maintains and improves functional vision in type 1 and type 2&#x000a0;diabetes mellitus patients.<xref ref-type="bibr" rid="article-38795.r10">[10]</xref>&#x000a0;However, ALA can be orally dosed between 600 mg and 1800 mg daily for up to 6 months.</p>
        <p>Intravenous injection:&#x000a0;The study shows evidence for IV treatment of 600 mg daily in improving positive neuropathic symptoms and neuropathic deficits.<xref ref-type="bibr" rid="article-38795.r11">[11]</xref></p>
        <p>
<bold>Special Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> No research has examined the effects of hepatic impairment on ALA dosing. Research has examined ALA's role in treating certain liver conditions.<xref ref-type="bibr" rid="article-38795.r12">[12]</xref><xref ref-type="bibr" rid="article-38795.r13">[13]</xref></p>
        <p><bold>Renal impairment:</bold> There is no research documenting dose adjustments of ALA for patients with renal impairment. Some research has examined the role of ALA and other compounds in reducing oxidative stress in diabetic nephropathy.<xref ref-type="bibr" rid="article-38795.r14">[14]</xref></p>
        <p><bold>Pregnant women:</bold> To date, research shows ALA supplementation during pregnancy is safe.<xref ref-type="bibr" rid="article-38795.r15">[15]</xref>&#x000a0;More data is needed to establish the role of ALA supplementation in pregnancy.</p>
        <p><bold>Breastfeeding women:</bold> There is a lack of reliable data regarding the safety of alpha-lipoic use during breastfeeding.&#x000a0;</p>
        <p><bold>Pediatric and older patients:</bold> There is no data regarding the use of ALA in these specific patient populations.</p>
      </sec>
      <sec id="article-38795.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>ALA is considered a safe supplementation without any adverse effects.&#x000a0;One study supports the safety of the drug,&#x000a0;and an adult can take up to 2400 mg without experiencing any harmful adverse effects.<xref ref-type="bibr" rid="article-38795.r16">[16]</xref>&#x000a0;High doses of ALA are not recommended as&#x000a0;higher doses&#x000a0;provide&#x000a0;no additional benefits.&#x000a0;The most common&#x000a0;adverse effects reported with ALA are headache, heartburn, nausea, and vomiting.<xref ref-type="bibr" rid="article-38795.r17">[17]</xref></p>
        <p>A&#x000a0;1996 ALA study on&#x000a0;6 rhesus monkeys showed that excess lethal doses in primates would cause hepatic necrosis.&#x000a0;Researchers noted that 3 out of 6 monkeys that received 90 mg/kg to 100 mg/kg of intravenous ALA exhibited large necrotic areas in the muscles of their thighs, the liver, the heart, and the kidneys.&#x000a0;This situation led the researchers to conclude that exceptionally high doses of&#x000a0;IV ALA can produce the same symptoms that smaller doses prevent.<xref ref-type="bibr" rid="article-38795.r18">[18]</xref></p>
      </sec>
      <sec id="article-38795.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Box Warning</bold>
</p>
        <p>There are no box warnings for ALA.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>There are very few studies on the contraindications of ALA supplementation. However, due to the adverse effects of ALA on animals and due to ALA's physiological effects, one should consult with a doctor if they have the following conditions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Liver disease</p>
          </list-item>
          <list-item>
            <p>Consumption of large amounts of alcohol</p>
          </list-item>
          <list-item>
            <p>Diabetes (ALA is known to lower blood sugar)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Thyroid disorder</p>
          </list-item>
          <list-item>
            <p>Thiamine deficiency&#x000a0;</p>
          </list-item>
        </list>
        <p>Also, one should stop using ALA immediately if an allergic reaction occurs, such as skin rash, nausea, or vomiting. There is no established contraindication&#x000a0;for using ALA in pregnant women and infants.</p>
      </sec>
      <sec id="article-38795.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Though ALA intoxication is extremely rare, close monitoring is necessary for children who are around diabetic patients.&#x000a0;A case of ALA intoxication was reported in which the patient attempted to commit suicide.&#x000a0;Therefore,&#x000a0;it is vital to monitor ALA use in people who have suicidal thoughts or psychological issues.<xref ref-type="bibr" rid="article-38795.r19">[19]</xref> Patients admitted to the emergency room with acute ALA poisoning usually present with tachycardia, neurologic effects, metabolic acidosis, and T wave inversion in the EKG.<xref ref-type="bibr" rid="article-38795.r20">[20]</xref></p>
        <p>There is no established therapeutic index of ALA in humans. However, studies show that safety&#x000a0;dosage&#x000a0;is defined in animals. The experimental values are 400 mg/kg to 500 mg/kg for dogs, 30 mg/kg for cats, and 500 mg/kg for mice. In animal studies, high levels of ALA were reported to cause hepatotoxicity, apathy, confusion, and hypokinesis.<xref ref-type="bibr" rid="article-38795.r7">[7]</xref>&#x000a0;Therefore, patient monitoring may be advisable when under&#x000a0;high doses of ALA.</p>
      </sec>
      <sec id="article-38795.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>ALA is generally considered a safe drug. A daily dose of 200 mg/day to 2400 mg/day of ALA is deemed safe without&#x000a0;significant adverse effects. However, there is no reported safe dose in children.<xref ref-type="bibr" rid="article-38795.r21">[21]</xref></p>
        <p>A notable case in literature demonstrated status epilepticus (SE) that subsided within a few days. The seizures were treated per normal standards for SE.<xref ref-type="bibr" rid="article-38795.r22">[22]</xref></p>
        <p>In&#x000a0;the last&#x000a0;2 decades, there have been few reported cases of ALA toxicity in humans. Most of these cases occur in children and are treatable. Though there is no established lethal dosage of ALA for humans, studies have shown that a high dose of&#x000a0;121 mg/kg body weight/day was associated with alterations in liver enzymes and liver function.<xref ref-type="bibr" rid="article-38795.r16">[16]</xref>&#x000a0;Therefore, there are potentially harmful&#x000a0;adverse effects from overdosing on ALA, and more studies are necessary to determine the toxicity.&#x000a0;</p>
      </sec>
      <sec id="article-38795.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective and safe use of ALA supplements require communication between healthcare team members, including primary care clinicians and pharmacists. Patients should consult their primary clinician before using ALA, and these frontline resources can provide patients with the proper dosage and safety information. ALA is a generally safe supplement that can be purchased over the counter, but clinicians can monitor and treat any adverse events. It is essential to have appropriate cooperation between interprofessional team members to ensure that the patient receives optimal benefits from ALA supplementation.</p>
      </sec>
      <sec id="article-38795.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=38795&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=38795">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/38795/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=38795">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-38795.s11">
        <title>References</title>
        <ref id="article-38795.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cadenas</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Lipoic acid: energy metabolism and redox regulation of transcription and cell signaling.</article-title>
            <source>J Clin Biochem Nutr</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>48</volume>
            <issue>1</issue>
            <fpage>26</fpage>
            <page-range>26-32</page-range>
            <pub-id pub-id-type="pmid">21297908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Golbidi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Badran</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Laher</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Diabetes and alpha lipoic Acid.</article-title>
            <source>Front Pharmacol</source>
            <year>2011</year>
            <volume>2</volume>
            <fpage>69</fpage>
            <pub-id pub-id-type="pmid">22125537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirlich</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kiok</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sandig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lochs</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grune</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Alpha-lipoic acid prevents ethanol-induced protein oxidation in mouse hippocampal HT22 cells.</article-title>
            <source>Neurosci Lett</source>
            <year>2002</year>
            <month>Aug</month>
            <day>09</day>
            <volume>328</volume>
            <issue>2</issue>
            <fpage>93</fpage>
            <page-range>93-6</page-range>
            <pub-id pub-id-type="pmid">12133563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Packer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Witt</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Tritschler</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>alpha-Lipoic acid as a biological antioxidant.</article-title>
            <source>Free Radic Biol Med</source>
            <year>1995</year>
            <month>Aug</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>227</fpage>
            <page-range>227-50</page-range>
            <pub-id pub-id-type="pmid">7649494</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vallianou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Evangelopoulos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koutalas</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Alpha-lipoic Acid and diabetic neuropathy.</article-title>
            <source>Rev Diabet Stud</source>
            <year>2009</year>
            <season>Winter</season>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>230</fpage>
            <page-range>230-6</page-range>
            <pub-id pub-id-type="pmid">20043035</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frondoza</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Fortuno</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Grzanna</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Ownby</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Au</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Rashmir-Raven</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>&#x003b1;-Lipoic Acid Potentiates the Anti-Inflammatory Activity of Avocado/Soybean Unsaponifiables in Chondrocyte Cultures.</article-title>
            <source>Cartilage</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>304</fpage>
            <page-range>304-312</page-range>
            <pub-id pub-id-type="pmid">29156944</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shay</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Moreau</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential.</article-title>
            <source>Biochim Biophys Acta</source>
            <year>2009</year>
            <month>Oct</month>
            <volume>1790</volume>
            <issue>10</issue>
            <fpage>1149</fpage>
            <page-range>1149-60</page-range>
            <pub-id pub-id-type="pmid">19664690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Karunakaran</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Jeoung</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Jeon</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IK</given-names>
              </name>
            </person-group>
            <article-title>Physiological effect and therapeutic application of alpha lipoic acid.</article-title>
            <source>Curr Med Chem</source>
            <year>2014</year>
            <volume>21</volume>
            <issue>32</issue>
            <fpage>3636</fpage>
            <page-range>3636-45</page-range>
            <pub-id pub-id-type="pmid">25005184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ji</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Luan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zang</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Alpha-lipoic acid exerts anti-inflammatory effects on lipopolysaccharide-stimulated rat mesangial cells via inhibition of nuclear factor kappa B (NF-&#x003ba;B) signaling pathway.</article-title>
            <source>Inflammation</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>510</fpage>
            <page-range>510-9</page-range>
            <pub-id pub-id-type="pmid">24962643</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x00119;bka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Serkies-Minuth</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Raczy&#x00144;ska</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Effect of the administration of alpha-lipoic acid on contrast sensitivity in patients with type 1 and type 2 diabetes.</article-title>
            <source>Mediators Inflamm</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>131538</fpage>
            <pub-id pub-id-type="pmid">24665163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ziegler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kempler</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vargha</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.</article-title>
            <source>Diabet Med</source>
            <year>2004</year>
            <month>Feb</month>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>114</fpage>
            <page-range>114-21</page-range>
            <pub-id pub-id-type="pmid">14984445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>&#x003b1;-Lipoic acid improves mitochondrial biogenesis and dynamics by enhancing antioxidant and inhibiting Wnt/Ca<sup>2+</sup> pathway to relieve fluoride-induced hepatotoxic injury.</article-title>
            <source>Chem Biol Interact</source>
            <year>2023</year>
            <month>Nov</month>
            <day>01</day>
            <volume>385</volume>
            <fpage>110719</fpage>
            <pub-id pub-id-type="pmid">37739047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dugbartey</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Alornyo</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Adams</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Atule</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Obeng-Kyeremeh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Amoah</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Adjei</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Targeting hepatic sulfane sulfur/hydrogen sulfide signaling pathway with &#x003b1;-lipoic acid to prevent diabetes-induced liver injury via upregulating hepatic CSE/3-MST expression.</article-title>
            <source>Diabetol Metab Syndr</source>
            <year>2022</year>
            <month>Oct</month>
            <day>13</day>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>148</fpage>
            <pub-id pub-id-type="pmid">36229864</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Darenskaya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kolesnikov</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Semenova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kolesnikova</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Diabetic Nephropathy: Significance of Determining Oxidative Stress and Opportunities for Antioxidant Therapies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2023</year>
            <month>Aug</month>
            <day>03</day>
            <volume>24</volume>
            <issue>15</issue>
            <pub-id pub-id-type="pmid">37569752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parente</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Colannino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bilotta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Espinola</surname>
                <given-names>MSB</given-names>
              </name>
              <name>
                <surname>Proietti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Neri</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Aragona</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Unfer</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Effect of Oral High Molecular Weight Hyaluronic Acid (HMWHA), Alpha Lipoic Acid (ALA), Magnesium, Vitamin B6 and Vitamin D Supplementation in Pregnant Women: A Retrospective Observational Pilot Study.</article-title>
            <source>Clin Pract</source>
            <year>2023</year>
            <month>Sep</month>
            <day>15</day>
            <volume>13</volume>
            <issue>5</issue>
            <fpage>1123</fpage>
            <page-range>1123-1129</page-range>
            <pub-id pub-id-type="pmid">37736936</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cremer</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Rabeler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Safety evaluation of alpha-lipoic acid (ALA).</article-title>
            <source>Regul Toxicol Pharmacol</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>46</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-41</page-range>
            <pub-id pub-id-type="pmid">16904799</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Theodosis-Nobelos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Papagiouvannis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tziona</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rekka</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Lipoic acid. Kinetics and pluripotent biological properties and derivatives.</article-title>
            <source>Mol Biol Rep</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>6539</fpage>
            <page-range>6539-6550</page-range>
            <pub-id pub-id-type="pmid">34420148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vigil</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berkson</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>AP</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of high doses of intravenous alpha lipoic Acid on liver mitochondria.</article-title>
            <source>Glob Adv Health Med</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>3</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <page-range>25-7</page-range>
            <pub-id pub-id-type="pmid">24753992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hadzik</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Grass</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mayatepek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Daldrup</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hoehn</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Fatal non-accidental alpha-lipoic acid intoxication in an adolescent girl.</article-title>
            <source>Klin Padiatr</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>226</volume>
            <issue>5</issue>
            <fpage>292</fpage>
            <page-range>292-4</page-range>
            <pub-id pub-id-type="pmid">24810749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emir</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Ozturan</surname>
                <given-names>IU</given-names>
              </name>
              <name>
                <surname>Yilmaz</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Alpha lipoic acid intoxicat&#x00131;on: An adult.</article-title>
            <source>Am J Emerg Med</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>1125.e3</fpage>
            <page-range>1125.e3-1125.e5</page-range>
            <pub-id pub-id-type="pmid">29559356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reljanovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Reichel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Rett</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lobisch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schuette</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tritschler</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Mehnert</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy.</article-title>
            <source>Free Radic Res</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>171</fpage>
            <page-range>171-9</page-range>
            <pub-id pub-id-type="pmid">10499773</pub-id>
          </element-citation>
        </ref>
        <ref id="article-38795.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tolunay</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>&#x000c7;elik</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>K&#x000f6;m&#x000fc;r</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gezgin</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Kaya</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>&#x000c7;elik</surname>
                <given-names>&#x000dc;</given-names>
              </name>
            </person-group>
            <article-title>A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature.</article-title>
            <source>Eur J Paediatr Neurol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>19</volume>
            <issue>6</issue>
            <fpage>730</fpage>
            <page-range>730-2</page-range>
            <pub-id pub-id-type="pmid">26216607</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
